Which of your patients could benefit from ARIKAYCE?

Advice from top experts

The Appropriate Patient

Which of your patients may be appropriate for ARIKAYCE + standard therapy?

Diane patient icon

Diane, 67 years old

Click to see Diane's journey to ARIKAYCE treatment

Icon button with downward arrow

Initial patient visit

Clinical presentation (>6 months)

  • Chronic cough
  • Sputum production
  • Fatigue

Medical history

  • Bronchiectasis
  • Hyperlipidemia
  • Osteoporosis
  • Sinusitis
  • Hemoptysis
  • Weight loss

Diagnostic results

Image of lung scan Icon Open
Imaging

Microbiologic results

  • 2 AFB stains and 2 cultures positive for MAC
  • Macrolide susceptible: MIC 2.5 µg/mL
  • Amikacin (IV) susceptible

Diagnosis is MAC lung disease based on

  • Symptomatic presentation
  • CT scan showing nodular bronchiectatic disease
  • Sputum cultures positive for MAC

Click to see Diane’s journey to ARIKAYCE treatment

Icon bracket pointing down Icon bracket pointing down
  • Initiated airway clearance and active monitoring
  • Month 1
  • Month 2
  • Close monitoring

    If treatment is not initiated, patients should be closely monitored to identify any clinical and/or radiographic progression.1

  • Began standard therapy according to guidelines
  • Month 4
  • Month 5
  • Month 6
  • Month 7
  • Month 8
  • May need more

    Although some patients can achieve culture conversion on initial guideline-recommended therapy, 20% to 40% experience treatment failure.2

  • Added ARIKAYCE per 2020 NTM Treatment Guidelines1
  • Month 10
  • Month 11
  • Treatment duration

    Guidelines recommend treating patients until culture negative on therapy for 12 months.1

Do you have a MAC patient like Diane?

Prescribing ARIKAYCE enrollment form icon
Prescribe ARIKAYCE
Right arrow icon
Eric patient icon

Eric, 59 years old

Click to see Eric’s journey to ARIKAYCE treatment

Icon button with downward arrow

Initial patient visit

Clinical presentation (>2 years)

  • Chronic cough
  • Excessive sputum production
  • Dyspnea
  • Fatigue
  • Hemoptysis
  • Emphysema

Medical history

  • COPD
  • Bronchiectasis
  • Cardiovascular disease

Diagnostic results

Image of lung scan Icon Open
Imaging

Microbiologic results

  • 1 AFB stain and 2 cultures positive for MAC
  • Macrolide susceptible: MIC 3 µg/mL
  • Amikacin (IV) susceptible: MIC 16 µg/mL*

Diagnosis is MAC lung disease based on

  • Symptomatic presentation
  • CT scan showing nodular bronchiectatic disease
  • Sputum cultures positive for MAC

Click to see Eric’s journey to ARIKAYCE treatment

Icon bracket pointing down Icon bracket pointing down
  • Initiated standard therapy + airway clearance
  • Month 1
  • Month 2
  • Ongoing monitoring

    Guidelines recommend carefully monitoring toxicity and assessing sputum cultures every 1-2 months during therapy.1

  • Month 3
  • Month 4
  • Month 5
  • Month 7
  • Month 8
  • Month 9
  • Month 10
  • Month 11
  • May need more

    Although some patients can achieve culture conversion on initial guideline-recommended therapy, 20% to 40% experience treatment failure.2

  • Added ARIKAYCE per 2020 NTM Treatment Guidelines1
  • Month 13
  • Month 14
  • Month 15
  • Treatment duration

    Guidelines recommend treating patients until culture negative on therapy for 12 months.1

Learn more about the

Clinical data of ARIKAYCE
Right arrow icon
Jan patient icon

Jan, 74 years old

Click to see Jan's journey to ARIKAYCE treatment

Icon button with downward arrow

Initial patient visit

Clinical presentation (1 year)

  • Fatigue
  • Weight loss

Medical history

  • Asthma
  • Osteopenia
  • GERD

Diagnostic results

Image of lung scan Icon Open
Imaging

Microbiologic results

  • 2 induced sputum cultures positive for MAC
  • Macrolide susceptible: MIC 2 µg/mL
  • Amikacin (IV) susceptible

Diagnosis is MAC lung disease based on

  • Symptomatic presentation
  • CT scan showing nodular bronchiectatic disease
  • Induced sputum cultures positive for MAC

Click to see Jan’s journey to ARIKAYCE treatment

Icon bracket pointing down Icon bracket pointing down
  • Initiated airway clearance and active monitoring
  • Personalized care

    Literature suggests personalizing clearance techniques for each patient, depending on the comprehensive care needed and taking into account other lung comorbidities and disease severity.3

  • Month 1
  • Began standard therapy according to guidelines
  • Month 3
  • Month 4
  • Month 5
  • Month 6
  • Month 7
  • Month 8
  • Month 9
  • May need more

    Although some patients can achieve culture conversion on initial guideline-recommended therapy, 20% to 40% experience treatment failure.2

  • Added ARIKAYCE per 2020 NTM Treatment Guidelines1
  • Month 11
  • Month 12
  • Month 13
  • Month 14

Learn more about the

Phase 3 trial
Right arrow icon

Patient Example

Additional Appropriate Patients

Footnote

*Patients enrolled in CONVERT had an IV amikacin MIC ≤64 μg/mL.4,5 The CONVERT trial is referred to as "Trial 1" in the ARIKAYCE full Prescribing Information.

AFB=acid-fast bacilli; CT=computed tomography; GERD=gastroesophageal reflux disease; IV=intravenous; MAC=Mycobacterium avium complex; MIC=minimum inhibitory concentration; NTM=nontuberculous mycobacteria.

References

  1. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1-e36.
  2. Koh WJ, Hong G, Kim SY, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57(5):2281-2285.
  3. McIlwaine M, Bradley J, Elborn JS, Moran F. Personalising airway clearance in chronic lung disease. Eur Respir Rev. 2017;26(143). doi:10.1183/16000617.0086-2016.
  4. ARIKAYCE [package insert]. Bridgewater, NJ: Insmed Incorporated; 2020.
  5. Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559-1569.